The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Assessment of Prostate Carcinoma Aggressiveness: Relation to68Ga-PSMA-11-PET/MRI and Gleason Score
Open accessAbstract
Background/Aim: To test the correlation of 68Ga-PSMA-11 uptake and the expression of PSMA (prostatic specific membrane antigen) with the Gleason score, apparent diffusion coefficient (ADC) and pharmacokinetic parameters obtained from dynamic contrast agent-enhanced MRI/PET. Patients and Methods: Forty newly diagnosed, therapy naïve patients with prostatic carcinoma (PC) (mean age of 56.7, range=34-79), who were referred for 68Ga-PSMA-11-PET/MRI for primary staging and had undergone radical prostatectomy (RAPE) were included in this prospective study. Their blood samples were tested for serum levels of prostate-specific antigen (PSA) and proPSA. The patients’ prostates were evaluated using whole-mount sections, which helped determine the extent and grade of the tumor; tests were performed to determine immunohistochemical PSMA expression. Results: A correlation between PSMA expression and the accumulation of 68Ga-PSMA-11 was found using the Spearman correlation coefficient (p=0.0011). A stronger correlation was found between Gleason patterns 3 or 4 and PSMA expression (p=0.06). Furthermore, the correlation of Gleason score with the overall 68Ga-PSMA-11 accumulation within the tumor or non-tumor tissue was found to be significant (p=0.0157). A significant relation was found only with the Kep elimination rate constant, which was stronger in Gleason pattern 4 than in Gleason pattern 3. A weaker correlation was found between the accumulation of 68Ga-PSMA-11 and Ktrans in Gleason pattern 4: the most significant relation being between ADCmin and Gleason pattern 3 and 4 (p=0.0074). The total size of the tumor correlated with levels of proPSA (p<0.0001), and its extra prostatic extension correlated with levels of proPSA (p<0.0001). Conclusion: 68Ga-PSMA-11 correlates well with the expression of PSMA. Gleason pattern 3 and 4 had a higher correlation with 68Ga-PSMA-11 levels than did Gleason pattern 5. Either no correlation, or a weak correlation, was established with pharmacokinetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“given the correlation of 68Ga-PSMA-11 uptake with PSMA expression and thus with therapeutic targeting of PSMA in patients with mCRPC (12,13).”
From Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial) (2024) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessment of 68 Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
Fendler, W. P., Calais, J., Eiber, M., Flavell, R. R., Mishoe, A., Feng, F. Y.-C., Nguyen, H. G., Reiter, R. E., Rettig, M. B., Okamoto, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0096 · Cited by 833
PET/MRI in prostate cancer: a systematic review and meta-analysis
Evangelista, L., Zattoni, F., Cassarino, G., Artioli, P., Cecchin, D., Moro, F. D., & Zucchetta, P. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05025-0 · Cited by 152
Chen, M., Zhang, Q. H., Zhang, C., Zhao, X., Marra, G., Gao, J., Lv, X., Zhang, B., Fu, Y. S., Wang, F., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221010 · Cited by 124
Rüschoff, J. H., Ferraro, D. A., Muehlematter, U. J., Laudicella, R., Hermanns, T., Rodewald, A., Moch, H., Eberli, D., Burger, I. A., & Rupp, N. J. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05501-1 · Cited by 93
Li, Y., Han, D., Wu, P., Ren, J., Ma, S., Zhang, J., Song, W., Lin, X., Jiao, D., Shi, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67385-9 · Cited by 39
PSMA uptake on [68Ga]-PSMA-11-PET/CT positively correlates with prostate cancer aggressiveness
Chen, M., Qiu, X., Zhang, Q. H., Zhang, C., Yi-Hua, Z. H. O. U., Zhao, X., Fu, Y. S., Wang, F., & Guo, H. (2022) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.19.03172-8 · Cited by 25
68Ga-PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue
Ferraro, D. A., Rupp, N. J., Donati, O. F., Messerli, M., Eberli, D., & Burger, I. A. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002473 · Cited by 20
Ferraro, D. A., Lehner, F., Becker, A. S., Kranzbühler, B., Kudura, K., Mebert, I., Messerli, M., Hermanns, T., Eberli, D., & Burger, I. A. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05058-5 · Cited by 13
Keegan, N. M., Bodei, L., & Morris, M. J. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.03.012 · Cited by 13
Fassbind, S., Ferraro, D. A., Stelmes, J., Fankhauser, C. D., Gückenberger, M., Kaufmann, P. A., Eberli, D., Burger, I. A., & Kranzbühler, B. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01646-z · Cited by 8
Cited by
Kuo, P. H., Morris, M. J., Hesterman, J., Kendi, A. T., Rahbar, K., Wei, X. X., Fang, B., Adra, N., Garje, R., Michalski, J. M., et al. (2024) · Radiology · doi:10.1148/radiol.233460 · Cited by 119
68Ga-PSMA PET/CT and Prostate Cancer Diagnosis: Which SUVmax Value?
Pepe, P., Pepe, L., Tamburo, M., Marletta, G., Savoca, F., Pennisi, M., & Fraggetta, F. (2023) · In Vivo · doi:10.21873/invivo.13211 · Cited by 58
Targeted Biopsy in Men High Risk for Prostate Cancer: 68Ga-PSMA PET/CT Versus mpMRI
Pepe, P., & Pennisi, M. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.06.007 · Cited by 51
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Zhou, L., Lu, Y., Liu, W., Wang, S., Wang, L., Zheng, P., Zi, G., Liu, H., Liu, W., & Wei, S. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00493-8 · Cited by 44
Advances in radiology and pathology of prostate cancer: a review for the pathologist
Pepe, P., Fandella, A., Barbera, M., Martino, P., Merolla, F., Caputo, A., & Fraggetta, F. (2024) · Pathologica · doi:10.32074/1591-951x-925 · Cited by 13
Chen, D. C., Huang, S., Papa, N. P., Siva, S., Bolton, D. M., Lawrentschuk, N., Emmett, L., Murphy, D. G., Hofman, M. S., & Perera, M. (2025) · British Journal of Urology · doi:10.1111/bju.16608 · Cited by 13
Albano, D., Tasevski, S., Sadeghi, R., Treglia, G., & Rizzo, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1827510 · Cited by 3
Weitzer, F., Pernthaler, B., Plhak, E., Riedl, R., & Aigner, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-35628-0 · Cited by 3
Yang, Y.-J., Min, K., Tae, J. H., Lee, C. U., Choi, J., Kim, J. H., Yang, E.-J., Nguyen, T. T., & Choi, S. Y. (2025) · Prostate International · doi:10.1016/j.prnil.2025.05.002 · Cited by 2
Sadeghpour, S., Saidi, B., Sahafi, P., Maleki, F., Ranjbar, S., Ghorbani, M., Hakim, H. G., Aghaee, A., Fanti, S., Beheshti, M., et al. (2026) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2026.05.005 · Cited by 2
Growth Patterns of Prostate Cancers Undetected by Prostate 3T Multiparametric MRI
Chang, K.-P., Hsieh, P., Lin, W., & Chang, H. (2024) · In Vivo · doi:10.21873/invivo.13508 · Cited by 1
Potential Clinical Applications of Dedicated Prostate Positron Emission Tomography
Castellucci, P., Mei, R., Farolfi, A., Nanni, C., & Fanti, S. (2023) · PET Clinics · doi:10.1016/j.cpet.2023.09.003
Elsadawy, M. E. I., Omar, Y., & Taha, N. M. (2024) · The Egyptian Journal of Radiology and Nuclear Medicine · doi:10.1186/s43055-024-01351-7
PSMA PET/CT in the Diagnosis of Prostate Cancer
Pepe, P. (2025) · Springer eBooks · doi:10.1007/978-3-031-78135-3_31
Distribution of 68Ga-PSMA-11 in tissues during prostate cancer imaging
Odvody, M., Looseová, M., Ferdová, E., Baráková, T., Pernický, J., & Ferda, J. (2026) · Česká radiologie · doi:10.55095/cesradiol2026/013
Self-citationGonzález-Martínez, C. A., Alcacio-Mendoza, J. A., Hernández-Ramírez, R., Lagos-Beitz, H. E., Méndez, G. T.-G., Gabilondo-Navarro, F. B., & Castillejos-Molina, R. (2026) · The Prostate · doi:10.1002/pros.70220
Metadata
- Authors
- FERDA, J., HES, O., HORA, M., FERDOVÁ, E., PERNICKÝ, J., RUDNEV, V., PECEN, L., TOPOLČAN, O., & MÍRKA, H.
- Affiliations
- Charles University (CZ)
- Venue
- Anticancer Research
- Published
- 2022-12-30
- Volume
- 43
- Issue
- 1
- Pages
- 449-453
- ISSN
- 0250-7005 (ISSN-L)
- 1791-7530
- OpenAlex
- W4313454203
- Cited by
- 16
- References
- 11
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 5 · 2023: 4
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Anticancer Research (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Univerzita Karlova v Praze (00669806)
- Fakultní Nemocnice Plzen (00669806)
- Topics
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- 68Ga-PSMA-11, prostate cancer, Gleason score, PSMA expression, tumor aggressiveness, apparent diffusion coefficient, pharmacokinetic parameters, Ktrans, proPSA, PET/MRI, radical prostatectomy, tumor staging
- MeSH terms
- Positron Emission Tomography Computed Tomography, Carcinoma, Edetic Acid, Gallium Isotopes, Gallium Radioisotopes, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Oligopeptides, Prospective Studies, Prostate, Prostatic Neoplasms, Positron-Emission Tomography, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
